uniQure Stock Plunges 37% on Mixed Huntington's Disease Trial Data

Key Facts

1uniQure stock dropped 37.14% following a four-year data update for its AMT-130 gene therapy.

2The therapy's effectiveness in slowing disease progression decreased from 80% at three years to 44% at four years.

3H.C. Wainwright maintained a 'Buy' rating despite the mixed results and failure to achieve statistical significance.

uniQure stock dropped 37.14% following a four-year data update for its AMT-130 gene therapy for Huntington's disease. Reuters reported that the therapy's effectiveness in slowing disease progression decreased to 44% at four years, down from the 80% observed at the three-year mark. According to Financial Modeling Prep, the treatment failed to achieve statistical significance in this latest trial update.

H.C. Wainwright maintained a "Buy" rating for the stock on September 29, 2026, despite the mixed results, noting that the three-year data remains the primary basis for regulatory approval applications with the FDA. QURE closed at $39.11 on September 28, 2026, prior to the clinical update that triggered the significant sell-off.